NCT01611025

Brief Summary

This is a retrospective, multicentre, observational study to assess the trends in antibiotic utilization and hospital ecology with respect to susceptibility patterns of selected bacterial isolates to the utilized antibiotics.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2011

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 1, 2011

Completed
8 months until next milestone

First Posted

Study publicly available on registry

June 4, 2012

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

June 4, 2012

Status Verified

May 1, 2012

First QC Date

October 1, 2011

Last Update Submit

June 1, 2012

Conditions

Infectious Diseases

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

selected bacterial isolates, such as but not limited to Pseudomonas aeruginosa, Acinetobacter Baumannii and Enterobacteriaceae species

You may qualify if:

  • the susceptibility of Pseudomonas aeruginosa
  • the susceptibility of Escherichia coli (ESBL and Non-ESBL producing strains)
  • the susceptibility of Klebsiella pneumoniae(ESBL and Non-ESBL producing strains)
  • the susceptibility of Enterobacter cloacae
  • the susceptibility of Enterobacter aerogenes
  • the susceptibility of Acinetobacter baumannii
  • antibiotic utilization data of carbapenems: Ertapenem, Meropenem, Imipenem
  • antibiotic utilization data of Penicillins: Piperacillin/Tazobactam
  • antibiotic utilization data of cephalosporins: Ceftriaxone, Cefotaxime, Flomoxef, Cefoperazone, Ceftazidime, cefepime, Cefpirome
  • antibiotic utilization data of Aztreonam,
  • antibiotic utilization data of fluoroquinolones: Ciprofloxacin, Levofloxacin
  • antibiotic utilization data of aminomethylcyclines: Tigecycline

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Communicable Diseases

Condition Hierarchy (Ancestors)

InfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Fu-Der Wang, M.D.

    Taipei Veterans General Hospital, Taiwan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 1, 2011

First Posted

June 4, 2012

Study Start

June 1, 2011

Study Completion

December 1, 2013

Last Updated

June 4, 2012

Record last verified: 2012-05